LINC01356 and neoplasm: Last, to substantiate the significance of LIMp27 with respect to in vivo tumor responses against DNA‐damaging drugs, we treated nu/nu mice carrying HT‐29.shLIMp27 and HT‐29.shCtrl xenografts with Dox, oxaliplatin, or Dox in combination with oxaliplatin.